11.19.13
Chicago, Ill.-based Positron Corporation, a nuclear medicine healthcare company, has appointed Joseph G. Oliverio as its new president. Oliverio will direct the company’s cardiac PET (positron emission tomography) mission and oversee Positron’s PET technology, radiopharmaceutical partnerships, clinical and technical applications for new customer sales and exiting users.
Joseph Oliverio has been a member of Positron’s board of directors since 2006 and has served as its president, chief technical officer and executive director of PET during that time. According to the company, Oliverio has been instrumental in guiding the development and introduction of Positron’s cardiac PET technology and has provided the vision of its molecular imaging strategy since joining the company. Oliverio was a pioneer as chief operating officer for the first freestanding heart disease reversal and prevention clinic guided by PET, and the first community based hospital offering cardiac PET in the emergency room setting, combined with an innovative heart disease reversal program. As a certified nuclear medicine technologist, Oliverio has performed over 13,000 cardiac studies on Positron imaging systems.
“I am excited to lead the company’s PET initiatives as president of Positron,” said Olivieri. “We are aggressively pursuing a complete cardiac PET solution from radioisotopes, radiopharmaceuticals, imaging devices, clinical guidance and innovative financing structures. Positron is ideally positioned to take a leadership role in the nuclear cardiology industry. The caliber of the team and the Company’s history, coupled with its strong market positioning, makes this a tremendous opportunity.”
“Over the years, Joe Oliverio’s knowledge of the cardiac PET industry and history with the company has been critical to the development of Positron’s technology and vertically integrated business plan,” said Patrick G. Rooney, CEO of Positron. “The demand for cardiac PET is stronger than ever and Joe’s expertise is ideally suited to execute Positron’s cardiac mission and to facilitate the growth of this modality.”
Positron Corporation focuses on nuclear cardiology, and provides an end-to-end solution for cardiac PET.
Joseph Oliverio has been a member of Positron’s board of directors since 2006 and has served as its president, chief technical officer and executive director of PET during that time. According to the company, Oliverio has been instrumental in guiding the development and introduction of Positron’s cardiac PET technology and has provided the vision of its molecular imaging strategy since joining the company. Oliverio was a pioneer as chief operating officer for the first freestanding heart disease reversal and prevention clinic guided by PET, and the first community based hospital offering cardiac PET in the emergency room setting, combined with an innovative heart disease reversal program. As a certified nuclear medicine technologist, Oliverio has performed over 13,000 cardiac studies on Positron imaging systems.
“I am excited to lead the company’s PET initiatives as president of Positron,” said Olivieri. “We are aggressively pursuing a complete cardiac PET solution from radioisotopes, radiopharmaceuticals, imaging devices, clinical guidance and innovative financing structures. Positron is ideally positioned to take a leadership role in the nuclear cardiology industry. The caliber of the team and the Company’s history, coupled with its strong market positioning, makes this a tremendous opportunity.”
“Over the years, Joe Oliverio’s knowledge of the cardiac PET industry and history with the company has been critical to the development of Positron’s technology and vertically integrated business plan,” said Patrick G. Rooney, CEO of Positron. “The demand for cardiac PET is stronger than ever and Joe’s expertise is ideally suited to execute Positron’s cardiac mission and to facilitate the growth of this modality.”
Positron Corporation focuses on nuclear cardiology, and provides an end-to-end solution for cardiac PET.